The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer

Therapeutic Advances in Gastroenterology

Volumn 10, Issue 6, 2017, Pages 507-520

  Lee, Hwajeong ^a,b   Ross, Jeffrey S ^a,b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b FOUNDATION MEDICINE   (United States)

Author keywords

biliary tract cancer; cholangiocarcinoma; comprehensive genomic profiling; gallbladder cancer; genomic alteration; next generation sequencing; precision medicine; targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; VASCULOTROPIN;

BILE DUCT CANCER; BILE DUCT CARCINOMA; BIOINFORMATICS; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CLINICAL OUTCOME; EGFR GENE; ERBB2 GENE; FGFR2 GENE; FUSION GENE; GENE MUTATION; GENETIC BACKGROUND; GENETIC SCREENING; HUMAN; IDH1 GENE; IDH2 GENE; MET GENE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RARE DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVAL TIME; SYSTEMIC THERAPY; VEGF GENE;

EID: 85019115922     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X17698090     Document Type: Review

References (71)

1. Abou-Alfa G., Anderson J., Chapman W., Choti M., Forbes S., Gores G., et al. (2016) Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol 7: 819-827.
2. Ahn D., Javle M., Ahn C., Jain A., Mikhai S., Noonan A., et al. (2016) Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer 122: 3657-3666.
3. Al-Shamsi H., Anand D., Shroff R., Jain A., Zuo M., Conrad C., et al. (2016) BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. J Gastrointest Oncol 7: 556-561.
4. Andia M., Hsing A., Andreotti G., Ferreccio C., (2008) Geographic variation of gallbladder cancer mortality and risk factors in Chile: a population-based ecologic study. Int J Cancer 123: 1411-1416.
5. Ang C., (2015) Role of the fibroblast growth factor receptor axis in cholangiocarcinoma. J Gastroenterol Hepatol 30: 1116-1122.
6. Arai Y., Totoki Y., Hosoda F., Shirota T., Hama N., Nakamura H., et al. (2014) Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59: 1427-1434.
7. Augustine M., Fong Y., (2014) Epidemiology and risk factors of biliary tract and primary liver tumors. Sur Oncol Clin N Am 23: 171-188.
8. Banales J., Cardinale V., Carpino G., Marzioni M., Andersen J., Invernizzi P., et al. (2016) Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13: 261-280.
9. Bang Y., Van Cutsem E., Feyereislova A., Chung H., Shen L., Sawaki A., et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
10. Barat S., Bozko P., Chen X., Scholta T., Hanert F., Götze J., et al. (2016) Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog 55: 2037-2050.
11. Bekaii-Saab T., Phelps M., Li X., Saji M., Goff L., Kauh J., et al. (2011) Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29: 2357-2363.
12. Borger D., Tanabe K., Fan K., Lopez H., Fantin V., Straley K., et al. (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17: 72-79.
13. Borodovsky A., Salmasi V., Turcan S., Fabius A., Baia G., Eberhart C., et al. (2013) 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 4: 1737-1747.
14. Bose R., Kavuri S., Searleman A., Shen W., Shen D., Koboldt D., et al. (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3: 224-237.
15. Bridgewater J., Lopes A., Beare S., Duggan M., Lee D., Ricamara M., et al. (2016) A phase 1b study of selumetinib in combination with cisplatin and gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer 16: 153.
16. Buzzoni R., Pusceddu S., Bajetta E., De Braud F., Platania M., Iannacone C., et al. (2014) Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Ann Oncol 25: 1597-1603.
17. Chan-On W., Nairismägi M., Ong C., Lim W., Dima S., Pairojkul C., et al. (2013) Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 45: 1474-1478.
18. Chong D., Zhu A., (2016) The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget 7: 46750-46767.
19. Churi C., Shroff R., Wang Y., Rashid A., Kang H., Weatherly J., et al. (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9: e115383.
20. Ewald F., Grabinski N., Grottke A., Windhorst S., Nörz D., Carstensen L., et al. (2013) Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer 133: 2065-2076.
21. George T., Frampton G., Sun J., Gowen K., Kennedy M., Greenbowe J., et al. (2016) Tumor mutational burden as a potential biomarker for PD-1/PD-L1 therapy in colorectal cancer. J Clin Oncol 34: abstract 3587.
22. Global Burden of Disease Cancer Collaboration (2015) The Global Burden of Cancer 2013. JAMA Oncol 1: 505-527.
23. Goyal L., Deshpande V., Chung D., Groeschl R., Gamblin T., Zhu A., (2014) Mismatch repair protein loss and microsatellite instability in cholangiocarcinoma. J Clin Oncol 32: abstract 237.
24. Graham R., Barr Fritcher E., Pestova E., Schulz J., Sitailo L., Vasmatzis G., et al. (2014) Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol 45: 1630-1638.
25. Jain A., Javle M., (2016) Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol 7: 797-803.
26. Jain A., Kwong L., Javle M., (2016) Genomic profiling of biliary tract cancers and implications for clinical practice. Curr Treat Options in Oncol 17: 58.
27. Jang S., Chun S., Hong S., Sung C., Park H., Kang H., et al. (2014) High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Mod Pathol 27: 731-739.
28. Javle M., Bekaii-Saab T., Jain A., Wang Y., Kelley R., Wang K., et al. (2016) Biliary cancer: utility of next-generation sequencing for clinical management. Cancer 122: 3838-3847.
29. Javle M., Churi C., Kang H., Shroff R., Janku F., Surapaneni R., et al. (2015) HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol 8: 58.
30. Jiao Y., Pawlik T., Anders R., Selaru F., Streppel M., Lucas D., et al. (2013) Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45: 1470-1473.
31. Khan S., Toledano M., Taylor-Robinson S., (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10: 77-82.
32. Kim S., Jang K., Lee J., Jang H., Choi H., Jang H., et al. (2015) Molecular subgroup analysis of clinical outcomes in a phase 3 study of gemcitabine and oxaliplatin with or without erlotinib in advanced biliary tract cancer. Transl Oncol 8: 40-46.
33. Kongpetch S., Jusakul A., Ong C., Lim W., Rozen S., Tan P., et al. (2015) Pathogenesis of cholangiocarcinoma: from genetics to signalling pathways. Best Pract Res Clin Gastroenterol 29: 233-244.
34. Le D., Uram J., Wang H., Bartlett B., Kemberling H., Eyring A., et al. (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520.
35. Lee H., Wang K., Johnson A., Jones D., Ali S., Elvin J., et al. (2016) Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol 69: 403-408.
36. Lee J., Capanu M., O'Reilly E., Ma J., Chou J., Shia J., et al. (2013) A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer 109: 915-919.
37. Lee J., Park S., Chang H., Kim J., Choi H., Lee M., et al. (2012) Gemcitabine and oxaliplatin with or within erlotinib in advanced biliary-tract cancer: a multicenter, open-label, randomised, phase 3 study. Lancet Oncol 13: 181-188.
38. Li M., Zhang Z., Li X., Ye J., Wu X., Tan Z., et al. (2014) Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 46: 872-876.
39. Loaiza-Bonilla A., Clayton E., Furth E., O'Hara M., Morrissette J., (2014) Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience 8: 479.
40. Malhi H., Gores G., (2006) Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45: 856-867.
41. Matei D., Kelich S., Cao L., Menning N., Emerson R., Rao J., et al. (2007) PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther 6: 1951-1959.
42. McRee A., Sanoff H., Carlson C., Ivanova A., O'Neil B., (2015) A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Invest New Drugs 33: 1225-1231.
43. Mondesir J., Willekens C., Touat M., de Botton S., (2016) IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med 7: 171-180.
44. Nakamura H., Arai Y., Totoki Y., Shirota T., Elzawahry A., Kato M., et al. (2015) Genomic spectra of biliary tract cancer. Nat Genet 47: 1003-1010.
45. Nakanuma Y., Curado M., Franceschi S., et al.(2010) Intrahepatic cholangiocarcinoma. In: Bosman F., Carneiro F., Hruban R., Theise N., (eds) WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press, pp. 217-224.
46. Nathan H., Pawlik T., Wolfgang C., Choti M., Cameron J., Schulick R., (2007) Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 11: 1488-1496.
47. O'Neill E., Kolch W., (2004) Conferring specificity on the ubiquitous Raf/MEK signaling pathway. Br J Cancer 90: 283-288.
48. Ong C., Subimerb C., Pairojkul C., Wongkham S., Cutcutache I., Yu W., et al. (2012) Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 44: 690-693.
49. Poomphakwaen K., Promthet S., Kamsa-Ard S., Vatanasapt P., Chaveepojnkamjorn W., Klaewkla J., et al. (2009) Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: a nested case-control study. Asian Pac J Cancer Prev 10: 251-258.
50. Reck M., Rodríguez-Abreu D., Robinson A., Hui R., Cs'szi T., Fülöp A., et al. (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833.
51. Roa I., de Toro G., Schalper K., de Aretxabala X., Churi C., Javle M., et al. (2014) Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res 7: 42-48.
52. Rosen C., Heimbach J., Gores G., (2010) Liver transplantation for cholangiocarcinoma. Transpl Int 23: 692-697.
53. Ross J., Wang K., Gay L., Al-Rohil R., Rand J., Jones D., et al. (2014) New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 19: 235-242.
54. Scagliotti G., von Pawel J., Novello S., Ramlau R., Favaretto A., Barlesi F., et al. (2015) Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 33: 2667-2674.
55. Schumacher T., Bunse L., Pusch S., Sahm F., Wiestler B., Quandt J., et al. (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512: 324-327.
56. Shin H., Oh J., Masuyer E., Curado M., Bouvard V., Fang Y., et al. (2010) Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 101: 579-585.
57. Simbolo M., Fassan M., Ruzzenente A., Mafficini A., Wood L., Corbo V., et al. (2014) Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 5: 2839-2852.
58. Skipworth J., Olde Damink S., Imber C., Bridgewater J., Pereira S., Malagó M., et al. (2011) Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol Ther 34: 1063-1078.
59. Spigel D., Ervin T., Ramlau R., Daniel D., Goldschmidt J. Jr., Blumenschein G. Jr., (2013) Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31: 4105-4114.
60. Theelen W., Mittempergher L., Willems S., Bosma A., Peters D., van der Noort V., et al. (2016) FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer. J Pathol Clin Res 2: 223-233.
61. Valle J., Wasan H., Lopes A., Backen A., Palmer D., Morris K., et al. (2015) Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary cancer (ABC-03): a randomized phase 2 trial. Lancet Oncol 16: 967-978.
62. Valle J., Wasan H., Palmer D., Cunningham D., Anthoney A., Maraveyas A., et al. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281.
63. Wang Y., Ding X., Wang S., Moser C., Shaleh H., Mohamed E., et al. (2016) Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett 380: 163-173.
64. Wang P., Dong Q., Zhang C., Kuan P., Liu Y., Jeck W., et al. (2013) Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32: 3091-3100.
65. Welzel T., McGlynn K., Hsing A., O'Brien T., Pfeiffer R., (2006) Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 98: 873-875.
66. Wilson J., Kunnimalaiyaan S., Kunnimalaiyaan M., Gamblin T., (2015) Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. Cancer Cell Int 15: 13.
67. Yang R., Wang B., Chen Y., Li H., Hu J., Zou S., (2013) Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis. Anticancer Drugs 24: 871-877.
68. Yang X., Wang W., Wang C., Wang L., Yang M., Qi M., et al. (2014) Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncol Rep 32: 700-708.
69. Yoshikawa D., Ojima H., Iwasaki M., Hiraoka N., Kosuge T., Kasai S., et al. (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418-425.
70. Zhou Y., Zhao Y., Li B., Huang J., Wu L., Xu D., et al. (2012) Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer 12: 289.
71. Zou S., Li J., Zhou H., Frech C., Jiang X., Chu J., et al. (2014) Mutational landscape of intrahepatic cholangiocarcinoma. Nature Commun 5: 5696.